Literature DB >> 30779607

The Special Pathogens Research Network: Enabling Research Readiness.

Colleen S Kraft1, Mark G Kortepeter2, Bruce Gordon3, Lauren M Sauer4, Erica S Shenoy5, Daniel P Eiras6, LuAnn Larson7, Jennifer A Garland8, Aneesh K Mehta9, Kevin Barrett10, Connie S Price11, Caroline Croyle12, Lauren R West, Brooke Noren13, Susan Kline14, Christa Arguinchona15, Henry Arguinchona16, Jonathan D Grein17, Chad Connally18, Susan McLellan19, George F Risi20, Timothy M Uyeki21, Richard T Davey22, Jo Ellen Schweinle23, Michelle M Schwedhelm24, Melissa Harvey25, Richard C Hunt26, Christopher J Kratochvil27.   

Abstract

The 2013-2016 epidemic of Ebola virus disease (EVD) that originated in West Africa underscored many of the challenges to conducting clinical research during an ongoing infectious disease epidemic, both in the most affected countries of Guinea, Liberia, and Sierra Leone, as well as in the United States and Europe, where a total of 27 patients with EVD received care in biocontainment units. The Special Pathogens Research Network (SPRN) was established in the United States in November 2016 to provide an organizational structure to leverage the expertise of the 10 Regional Ebola and Other Special Pathogen Treatment Centers (RESPTCs); it was intended to develop and support infrastructure to improve readiness to conduct clinical research in the United States. The network enables the rapid activation and coordination of clinical research in the event of an epidemic and facilitates opportunities for multicenter research when the RESPTCs are actively caring for patients requiring a biocontainment unit. Here we provide an overview of opportunities identified in the clinical research infrastructure during the West Africa EVD epidemic and the SPRN activities to meet the ongoing challenges in the context of Ebola virus and other special pathogens.

Entities:  

Keywords:  Clinical research; Ebola virus disease; Investigational therapeutics; Special pathogens

Mesh:

Year:  2019        PMID: 30779607      PMCID: PMC6669031          DOI: 10.1089/hs.2018.0106

Source DB:  PubMed          Journal:  Health Secur        ISSN: 2326-5094


  22 in total

1.  The National Ebola Training and Education Center: Preparing the United States for Ebola and Other Special Pathogens.

Authors:  Christopher J Kratochvil; Laura Evans; Bruce S Ribner; John J Lowe; Melissa Cole Harvey; Richard C Hunt; Abbigail J Tumpey; Ryan P Fagan; Michelle M Schwedhelm; Sonia Bell; John Maher; Colleen S Kraft; Nicholas V Cagliuso; Sharon Vanairsdale; Angela Vasa; Philip W Smith
Journal:  Health Secur       Date:  2017 May/Jun

2.  A Highly Infectious Disease Care Network in the US Healthcare System.

Authors:  Aurora B Le; Paul D Biddinger; Philip W Smith; Jocelyn J Herstein; Deborah A Levy; Shawn G Gibbs; John J Lowe
Journal:  Health Secur       Date:  2017 May/Jun

3.  Ebola virus disease: 11 323 deaths later, how far have we come?

Authors:  Joseph A Lewnard
Journal:  Lancet       Date:  2018-06-29       Impact factor: 79.321

4.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

Review 5.  Ebola virus circulation in Africa: a balance between clinical expression and epidemiological silence.

Authors:  J P Gonzalez; V Herbreteau; J Morvan; E M Leroy
Journal:  Bull Soc Pathol Exot       Date:  2005-09

6.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

Authors:  K Mupapa; M Massamba; K Kibadi; K Kuvula; A Bwaka; M Kipasa; R Colebunders; J J Muyembe-Tamfum
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.

Authors:  Michael Jacobs; Emma Aarons; Sanjay Bhagani; Ruaridh Buchanan; Ian Cropley; Susan Hopkins; Rebecca Lester; Daniel Martin; Neal Marshall; Stephen Mepham; Simon Warren; Alison Rodger
Journal:  Lancet Infect Dis       Date:  2015-08-25       Impact factor: 25.071

8.  Clinical Management of Ebola Virus Disease in the United States and Europe.

Authors:  Timothy M Uyeki; Aneesh K Mehta; Richard T Davey; Allison M Liddell; Timo Wolf; Pauline Vetter; Stefan Schmiedel; Thomas Grünewald; Michael Jacobs; Jose R Arribas; Laura Evans; Angela L Hewlett; Arne B Brantsaeter; Giuseppe Ippolito; Christophe Rapp; Andy I M Hoepelman; Julie Gutman
Journal:  N Engl J Med       Date:  2016-02-18       Impact factor: 91.245

9.  First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease.

Authors:  Jenny Dörnemann; Chiara Burzio; Axelle Ronsse; Armand Sprecher; Hilde De Clerck; Michel Van Herp; Marie-Claire Kolié; Vesselina Yosifiva; Severine Caluwaerts; Anita K McElroy; Annick Antierens
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

Review 10.  The Role of the Laboratory and Transfusion Service in the Management of Ebola Virus Disease.

Authors:  Scott A Koepsell; Anne M Winkler; John D Roback
Journal:  Transfus Med Rev       Date:  2016-11-16
View more
  1 in total

1.  Advanced Preparation Makes Research in Emergencies and Isolation Care Possible: The Case of Novel Coronavirus Disease (COVID-19).

Authors:  David M Brett-Major; Elizabeth R Schnaubelt; Hannah M Creager; Abigail Lowe; Theodore J Cieslak; Jacob M Dahlke; Daniel W Johnson; Paul D Fey; Keith F Hansen; Angela L Hewlett; Bruce G Gordon; Andre C Kalil; Ali S Khan; Mark G Kortepeter; Christopher J Kratochvil; LuAnn Larson; Deborah A Levy; James Linder; Sharon J Medcalf; Mark E Rupp; Michelle M Schwedhelm; James Sullivan; Angela M Vasa; Michael C Wadman; Rachel E Lookadoo; John-Martin J Lowe; James V Lawler; M Jana Broadhurst
Journal:  Am J Trop Med Hyg       Date:  2020-05       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.